Clearside Biomedical, Inc. Income Statement | Understand Stock

Login

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
License and other revenue (includes $321 and $5,050 from a related party for the years ended December 31, 2024 and 2023, respectively)
Operating expenses:
Cost of goods sold
Research and development (includes $1,051 and $1,109 to a related party for the years ended December 31, 2024 and 2023, respectively)
General and administrative
Total operating expenses
Loss from operations
Other (expense) income
Interest income
Other income, net
Non-cash interest expense on liability related to the sales of future royalties
Other expense
Net loss
Weighted average shares outstanding — basic and diluted
Net loss per share of common stock - basic
Net loss per share of common stock - diluted
Weighted average shares outstanding - basic
Weighted average shares outstanding - diluted

Loading...

Comments